GNL Gut and Liver
  1. Thomas F. Stoop, Leonard W. F. Seelen, Freek R. van ’t Land, Kishan R. D. Lutchman, Susan van Dieren, Daan J. Lips, Erwin van der Harst, Geert Kazemier, Gijs A. Patijn, Ignace H. de Hingh, Jan H. Wijsman, Joris I. Erdmann, Sebastiaan Festen, Bas Groot Koerkamp, J. Sven D. Mieog, Marcel den Dulk, Martijn W. J. Stommel, Olivier R. Busch, Roeland F. de Wilde, Vincent E. de Meijer, Wouter te Riele, I. Quintus Molenaar, Casper H. J. van Eijck, Hjalmar C. van Santvoort, Marc G. Besselink, Anniek Vlijm, Bert A. Bonsing, C. Yung Nio, Derik-Jan de Groot, Elske Gootjes, Eran van Veldhuisen, Eric Manusama, Fenny Wit, Freek Daams, Geert Cirkel, Geertjan van Tienhoven, Irene van Hellemond, Johanna W. Wilmink, Judith de Vos-Geelen, Koop Bosscha, Leonie J. Mekenkamp, Maarten W. Nijkamp, Maartje Los, Marion B. van der Kolk, Marjolein Homs, Mark Ramaekers, Mike S. Liem, Miriam Wumkes, Nynke Michiels, Ronald van Dam, Rutger T. Theijse, Saskia Luelmo, Thomas L. Bollen, Ulf Neumann, Vincent Nieuwenhuijs, Werner Draaisma. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Ann Surg Oncol 2024;31:2640
    https://doi.org/10.1245/s10434-023-14650-6
  2. KV. Guggenberger, TA. Bley, S. Held, R. Keller, S. Flemming, A. Wiegering, CT. Germer, B. Kimmel, V. Kunzmann, I. Hartlapp, F. Anger. Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). European Journal of Radiology 2023;163:110834
    https://doi.org/10.1016/j.ejrad.2023.110834
  3. I. Hartlapp, D. Valta-Seufzer, J.T. Siveke, H. Algül, E. Goekkurt, G. Siegler, U.M. Martens, D. Waldschmidt, U. Pelzer, M. Fuchs, F. Kullmann, S. Boeck, T.J. Ettrich, S. Held, R. Keller, F. Anger, C.T. Germer, A. Stang, B. Kimmel, V. Heinemann, V. Kunzmann. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open 2022;7:100552
    https://doi.org/10.1016/j.esmoop.2022.100552
  4. Atsushi Oba, Marco Del Chiaro, Tsutomu Fujii, Keiichi Okano, Thomas F. Stoop, Y.H. Andrew Wu, Aya Maekawa, Yuta Yoshida, Daisuke Hashimoto, Toshitaka Sugawara, Yosuke Inoue, Minoru Tanabe, Masayuki Sho, Takashi Sasaki, Yu Takahashi, Ippei Matsumoto, Naoki Sasahira, Yuichi Nagakawa, Sohei Satoi, Richard D. Schulick, Yoo-Seok Yoon, Jin He, Jin-Young Jang, Christopher L. Wolfgang, Thilo Hackert, Marc G. Besselink, Kyoichi Takaori, Yoshifumi Takeyama. “Conversion surgery” for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022. Pancreatology 2023;23:712
    https://doi.org/10.1016/j.pan.2023.06.005
  5. Yong-Pyo Lee, Sung Yong Oh, Kwang Min Kim, Se-Il Go, Jung Hoon Kim, Seok Jae Huh, Jung Hun Kang, Jun Ho Ji. Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study. Cancers 2022;14:1950
    https://doi.org/10.3390/cancers14081950
  6. Yoshifumi Noda, Nisanard Pisuchpen, Nathaniel D. Mercaldo, Yurie Sekigami, Theodoros Michelakos, Anushri Parakh, Jennifer Y. Wo, Motaz Qadan, Cristina Ferrone, Keith D. Lillemoe, David P. Ryan, Jeffrey W. Clark, Carlos Fernandez-Del Castillo, Theodore S. Hong, Avinash R. Kambadakone. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol 2022;32:2470
    https://doi.org/10.1007/s00330-021-08304-y
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd